Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genes may determine who gets hooked or psychotic from cannabis

NCT ID NCT06058702

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study investigates how a person's genetic makeup influences their response to cannabis, including risk for addiction and psychosis. Healthy adults aged 21-60 receive either a very low or medium dose of THC (the active ingredient in cannabis) or a placebo intravenously. Researchers measure changes in mood, perception, thinking, and symptoms to see if certain genes predict stronger reactions. The goal is to better understand why some people develop cannabis use disorder or schizophrenia-related symptoms after using cannabis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Delta-9-THC (active ingredient in cannabis) given intravenously at very low and medium doses, compared to placebo
What this could lead to
If successful, this research could help identify genetic factors that make some people more vulnerable to cannabis addiction or psychosis, potentially guiding personalized prevention or treatment strategies.
What could go wrong
This is an early-phase study with a small sample, so findings may not apply broadly. The genetic links are complex and may not lead to clear clinical applications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 215 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Ages 21-60 years old Exclusion Criteria: * Major or unstable medical conditions based on history, the Structured Clinical Interview for DSM-5, collateral information, physical and laboratory examinations, ECG, and vital signs. * Cannabis naïve individuals * Positive pregnancy test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West Haven Veterans Affairs Medical Center

    RECRUITING

    West Haven, Connecticut, 06516, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.